On Monday, Novartis, a pharmaceutical giant, received U.S. approval for the Exelon Patch, which delivers a treatment for Alzheimer's disease through a skin patch, instead of through pill or capsule form. A press release stated that the U.S. Food and Drug Administration (FDA) had also approved the patch for treating mild to moderate Parkinson's disease dementia.
Patches for the delivery of medication aren't new, but more and more drug manufacturers seem to be studying this method of...
